Loading stock data…
4503.T
TSE¥2,386-82.50 (-3.34%)
Market ClosedLast close Apr 27
Astellas Pharma Inc.
Historical Price
Price (Line)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Astellas Pharma Inc. in the Healthcare sector is trading at ¥2,386. The stock is currently 12% below its 52-week high of ¥2,717, remaining 22.5% above its 200-day moving average. Technical signals show oversold RSI of 26 and bearish MACD signal, explaining why 4503.T maintains its current momentum and trend strength. The Whystock Score of 90/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 26) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price¥2,386
Potential Downside
38.4%
Whystock Fair Value¥1,471
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Buy
Mean target¥2,407+0.9%
Range¥1,600 – ¥2,950
Fundamentals
Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
¥4.44T
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
35.63
Beta
Defensive asset. Lower volatility than the S&P 500.
0.15
Div Yield
Strong income play. Yield provides a meaningful total return floor.
312.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
19.82%
Volume
Today's trading volume
5.69M
Recent News
Merck Says FDA Grants Priority Review to Keytruda-Padcev Combo for Bladder Cancer
Merck (MRK) said Monday that the US Food and Drug Administration (FDA) has granted priority review t
A Look At Astellas Pharma’s Valuation After A Strong Year Of Share Price Gains
What Astellas Pharma’s recent performance tells you now Astellas Pharma (TSE:4503) has drawn investor attention after a period in which the share price delivered double digit total returns over the past year, while reported annual revenue and net income declined. See our latest analysis for Astellas Pharma. Recent trading has been trending upward, with a 30 day share price return of 5.79% and a 90 day share price return of 16.81%. The 1 year total shareholder return of 113.99% points to...
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?
Here is how Astellas Pharma Inc. (ALPMY) and Adlai Nortye Ltd. Sponsored ADR (ANL) have performed compared to their sector so far this year.
Sutro Biopharma (STRO) Moves 7.4% Higher: Will This Strength Last?
Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year?
Here is how Astellas Pharma Inc. (ALPMY) and Cardinal Health (CAH) have performed compared to their sector so far this year.